Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — Investor Presentation (May 2026)
26 slides from Clearpoint Neuro's investor presentation, May 13, 2026
Slide 1: When Your Path Is Unclear, We Point the Way
WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdaq: CLPT May 2026 1 © 2026 CLEARPOINT NEURO
Slide 2: Disclaimer
DISCLAIMER Statements in this presentation and discussion concerning ClearPoint Neuro’s (the “Company’s”) plans, growth, and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future
Slide 3: Our Company: Precise Navigation to the Brain and Spine
Neuro Navigation and Robotics* Ablation Therapy and Access Neurocritical Management Biologics and Drug Delivery *Robotic product is in development phase. Commercialization is subject to successful development, testing, and applicable regulatory clearance. © 2026 CLEARPOINT NEURO OUR COMPANY We Enabl
Slide 4: The Future of Neuro Biologics and Drug Delivery is Here Today
The Future of Neuro Biologics and Drug Delivery is Here Today Our Company Stroke Rehabilitation (7.0m) More than 30 Million people in the U.S. alone are estimated to suffer from severe and debilitating neurological disorders. Neurological diseases cost Americans nearly $800 Billion annually. To redu
Slide 5: 60+ Active Pharma Partners, 10+ Programs Under FDA Expedited Review
The Future of Neuro Biologics and Drug Delivery is Here Today Our Company Of those 30 million patients, 2.1 million in the U.S. alone have disorders where a ClearPoint BioPharma Partner has already been accepted for FDA expedited review. Importantly, this gene therapy is labeled as a combination pro
Slide 6: Our 4-Phase Strategy Positions ClearPoint for Decades of Growth
Our 4-Phase Strategy Positions ClearPoint for Decades of Growth Our Company 1 With more than $100m of capital invested over the past 5 years, our large commercial footprint, rapidly expanding installed base, high-capacity manufacturing, stress-tested quality system, global regulatory reach and expan
Slide 7: This Unique ClearPoint Ecosystem Has Been Years in the Making
This Unique ClearPoint Ecosystem Has Been Years in the Making Design. Discovery. ClearPoint Neuro embraced the unmet need in neuro biologics and drug delivery and has invested more than $200m over the past 15 years to build a substantial headstart and leadership position. This expansive platform has
Slide 8: Our Installed Base Has Grown to More than 175 Active Global Centers
Active ClearPoint Installation (Additional Sites in Asia, EMEA, LATAM) Our Installed Base Has Grown to More than 175 Active Global Centers Funded. Foundation. © 2026 CLEARPOINT NEURO Over 170 employees worldwide focused exclusively on Neuro
Slide 9: ~50% of the Top Ranked Neurosurgery Programs use ClearPoint Technology
~50% of the Top Ranked Neurosurgery Programs use ClearPoint Technology Funded. Foundation. https://health.usnews.com/best-hospitals/rankings/neurology-and-neurosurgery - Posted July 29, 2025 Methodology components and weights summarized from publicly described Best Hospitals specialty ranking method
Slide 10: Stress-Tested QMS and Operations
Stress-Tested QMS and Operations Funded. Foundation. We have invested in our Research & Development, Quality and Manufacturing infrastructure to build confidence for both hospitals and biopharma partners We bring medical device expertise and regulatory combination product acumen to pharmaceutical co
Slide 11: Growth Continues Today While We Prepare for Commercial Drug Approvals
Growth Continues Today While We Prepare for Commercial Drug Approvals Funded. Foundation. For the year ended December 31, 2025 Unaudited, as of, and for the quarter ended March 31, 2026 For the Trailing Twelve Months (TTM) Including owned and licensed patents Solana Beach, CA HEADQUARTERS $37.0m(A)
Slide 12: Experienced Leadership in Place
Experienced Leadership in Place Funded. Foundation. Joe Burnett President & Chief Executive Officer Megan Faulkenberry Senior Vice President of Quality Jeremy Stigall Chief Business Officer Mary McNamara-Cullinane Senior Vice President of Regulatory Affairs Danilo D’Alessandro Chief Financial Office
Slide 13: Our 4-Pillar Growth Strategy
Our 4-Pillar Growth Strategy Fast. Forward. Collective $1.0B Existing Market Opportunity Today *Not all products cleared or approved in all territories. Increasing Global Scale with Clearances in 34 Countries Worldwide* Pre-Commercial Biologics & Drug Delivery Neurosurgery Navigation & Robotics Lase
Slide 14: Pillar 1: Pre-Commercial Biologics & Drug Delivery
Pillar 1: Pre-Commercial Biologics & Drug Delivery Fast. Forward. Leverage Both Commercial and In-Development Delivery and Navigation Tools SmartFlow Software & Biophysical Modeling in Collaboration with NE Scientific $300m+ Existing Market ClearPoint Neuro currently offers a boutique, neuro-focused
Slide 15: Pillar 2: Neuro Navigation & Robotics
Pillar 2: Neuro Navigation & Robotics Fast. Forward. ClearPoint will provide unmatched flexibility by having a single pre-planning software offering several workflows deployed via either MRI, iCT and eventually Robotics. This strategy balances the consistency of delivery that biopharma partners desi
Slide 16: Pillar 3: Laser Therapy & Access
Pillar 3: Laser Therapy & Access Fast. Forward. $75m+ Existing Market VelocityALPHA MRI Conditional Power Drill With Optional ClearPoint Navigation Synergies A Versatile Power Solution for SmartFrame in the MRI and OR ClearPoint Prism is a mobile laser therapy system featuring innovative non‑cooled
Slide 17: Pillar 4: Neurocritical Management
Pillar 4: Neurocritical Management Fast. Forward. ClearPoint’s recent acquisition of IRRAS expands the portfolio with a unique and disruptive solution for neurocritical care and intracranial fluid management. IRRAflow enables active irrigation and controlled drainage of hemorrhage, toxins, and clots
Slide 18: Clear and Continued Investment in ClearPoint's 4-Pillar Product Pipeline
Clear and Continued Investment in ClearPoint’s 4-Pillar Product Pipeline Fast. Forward. 1H 2026 2H 2026 1H 2027 2H 2027 2028+ 1 CAL Facility Operational Radiopharma Formulation MRI/CT Imaging Live GLP Study Capable Cell Culture Capability PET/SPECT Imaging Live Radiolabeling Active Histopathology Ac
Slide 19: 2026+ Product and Capability Plans by Pillar
3 2 2026+ LASER ABLATION THERAPY & ACCESS Add Ablation Coverage & AI Predictive Thermal Modeling Software Launch MRI Conditional Power Drill for Faster Procedure Times 4 NEUROCRITICAL CARE & ACTIVE CSF EXCHANGE Expand Existing Portfolio Into Multiple New Indications Launch Shoreline Software, Crania
Slide 20: What Does it Mean to be Essential to Future of Cell and Gene Therapy?
What Does it Mean to be Essential to Future of Cell and Gene Therapy? Essential. Everywhere. It starts by being unique. Our Essential. Everywhere. Strategy is to build a new market from the ground up where our unique ecosystem plays an essential role and enables 20,000 annual Cell & Gene Therapy pro
Slide 21: Our Unique Ecosystem Will Play An Essential Role for Cell and Gene Therapy
Our Unique Ecosystem Will Play An Essential Role for Cell and Gene Therapy Essential. Everywhere. Comprehensive Pre-Planning Navigation Software Modules Flexible Options for Surgeon Selected Navigation Including Frames, Robotics Multiple Biologic Specific & Co-Labeled Routes-of-Administration Every
Slide 22: ClearPoint Neuro Has 60+ Active Pharma Partners, 25+ Active Clinical Trials
Indication Parkinson’s Disease Epilepsy Huntington’s Rare Genetic Dementias Gliomas Neuromuscular Stroke …and more than 15 additional programs that are undisclosed and in preclinical development. © 2026 CLEARPOINT NEURO ClearPoint Neuro Has 60+ Active Pharma Partners, 25+ Active Clinical Trials Esse
Slide 23: 10+ Programs Are Already Under FDA Expedited Review and Enrolling
Parkinson's (Kenai) – RNDP-001 Parkinson's (Aspen) – ANPD001 Frontotemporal Dementia (AviadoBio) – AVB-101 Friedreich's Ataxia – (Undisclosed) Huntington's (uniQure) – AMT-130 AADC Deficiency (PTC) – KEBILIDI / Upstaza Parkinson's (AskBio) – AB-1005 Parkinson's (BlueRock) – BRT-DA01 Hunter Syndrome
Slide 24: Building Surgical Experience and Capacity to Prepare for Drug Commercialization
Building Surgical Experience and Capacity to Prepare for Drug Commercialization Essential. Everywhere. © 2026 CLEARPOINT NEURO Existing CLPT Navigation Site Experienced CLPT Navigation Site and Participant in Active CGT Trial
Slide 25: Commercial Drug Delivery and Pillar Plans 2026+
5 COMMERCIAL DRUG DELIVERY Add Capacity for 5,000 cell & gene therapy procedures Launch Co-Labeled Products with 10+ partners that are already under FDA Expedited Review across 8 Indications 3 2 2026+ LASER ABLATION THERAPY & ACCESS Add Ablation Coverage & AI Predictive Thermal Modeling Software Lau
Slide 26: Our 4-Phase Strategy Positions ClearPoint for Decades of Growth
Our 4-Phase Strategy Positions ClearPoint for Decades of Growth Our Company 1 With more than $100m of capital invested over the past 5 years, our large commercial footprint, rapidly expanding installed base, high-capacity manufacturing, stress-tested quality system, global regulatory reach and expan